@article{d1e2ecda732048cb9b352bf03f66ea9d,
title = "Blastemal predominant type Wilms tumor in Japan: Japan Children's Cancer Group",
abstract = "Background: Persistence of blastemal components after chemotherapy is a marker of poor outcome in Wilms tumor (WT). Recent reports from local Japanese areas have described pre-chemotherapy blastemal predominant type WT to also be a risk factor for relapse. The significance, however, of blastemal predominant WT remains to be evaluated in a larger study. This study retrospectively evaluated the prognostic significance of pre-chemotherapy blastemal predominant type WT in the Japan Wilms tumor Study (JWiTS) trials. Methods: The JWiTS trial (1996–2013) was a prospective, single-arm study. The outcomes of blastemal predominant type WT were retrospectively evaluated compared with non-blastemal type WT excluding anaplasia between 1996 and 2013. Relapse-free survival (RFS) and overall survival (OS) were estimated. Results: Of 319 primary renal tumors diagnosed by the central pathology review system, advanced stage of pre-chemotherapy blastemal predominant type WT (n = 53; 16.1%) occurred more frequently in older children than non-blastemal type WT (n = 225), and was especially frequent in female patients registered in the JWiTS trials. No significant difference in 10 years RFS and OS (78.8% vs 84.5; P = 0.201) or in 10 years RFS and OS (89.3% vs 93.5; P = 0.45) was seen between pre-chemotherapy blastemal predominant type and non-blastemal type WT. Conclusions: Relapse-free survival and OS are not significantly different between pre-chemotherapy blastemal predominant type and non-blastemal type WT.",
keywords = "Wilms tumor, blastemal component, blastemal predominant type, pediatric, renal tumor",
author = "Tsugumichi Koshinaga and Tetsuya Takimoto and Hajime Okita and Yukichi Tanaka and Eisuke Inoue and Takaharu Oue and Miwako Nozaki and Kunihiko Tsuchiya and Masayuki Haruta and Yasuhiko Kaneko and Masahiro Fukuzawa",
note = "Funding Information: 1Department of Pediatric Surgery, Nihon University School of Medicine, 2Division of Registration and Research for Childhood Cancer, and 3Department of Pediatric Hematology and Oncology Research, Research Institute, National Center for Child Health and Development, 4Department of Pathology, Keio University School of Medicine, Tokyo, 5Department of Pathology and Clinical Research Institute, Kanagawa Children{\textquoteright}s Medical Center, Yokohama, 6Division of Medical Informatics, St Marianna University School of Medicine, Kawasaki, 7Department of Pediatric Surgery, Hyogo College of Medicine, Hyogo, 8Department of Radiology, Dokkyo Medical University Saitama Medical Center, Koshigaya, 9Department of Pediatrics, Kyoto Prefectural University of Medicine, Graduate School of Medical Science, Kyoto, 10Research Institute for Clinical Oncology, Saitama Cancer Center, Saitama and 11Osaka Medical Center and Research Institute for Maternal and Child Health, Osaka, Japan Funding Information: The authors thank the members of the Japan Children{\textquoteright}s Cancer Group Renal Tumor Group: Kiyohiro Ando, Keishiro Amano, Motoko, Ohmura, Shigeko Kuwashima, Akihisa Sawada, Ryota Souzaki, Motoaki Chin, Kazumasa Nakamura, Seishiro Noudomi, Takehiko Kamijo, Koji Fukumoto, and Hir-oshi Yagasaki. This work was partially supported by the Practical Research for Innovative Cancer Control of the Japan Agency for Medical Research and Development, AMED, and Japan Society for the Promotion of Science (JSPS) KAKENHI Grant Number JP17H04356. Publisher Copyright: {\textcopyright} 2019 Japan Pediatric Society",
year = "2019",
month = apr,
doi = "10.1111/ped.13811",
language = "English",
volume = "61",
pages = "351--357",
journal = "Pediatrics International",
issn = "1328-8067",
publisher = "Wiley-Blackwell",
number = "4",
}
